Crossmark

Real-world analyses of major adverse cardiovascular events and mortality risk after androgen deprivation therapy initiation in black vs. white prostate cancer patients

Crossref DOI link: https://doi.org/10.1038/s41391-025-00963-y

Published Online: 2025-04-18

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Moul, Judd W. https://orcid.org/0000-0001-9228-8344
Boldt-Houle, Deborah M.

Roach, Mack III
Funding

Funding for this research was provided by:

Tolmar, Inc.
License Information

Text and Data Mining valid from 2025-04-18

Version of Record valid from 2025-04-18
More Information

Article History

Received: 1 October 2024

Revised: 21 February 2025

Accepted: 13 March 2025

First Online: 18 April 2025

Competing interests

: DMB-H is an employee of Tolmar, Inc. JWM and MR III have no conflicts of interest to declare. Editorial support was funded by Tolmar, Inc.

: All methods were performed in accordance with the relevant guidelines and regulations. This study was conducted in accordance with the Declaration of Helsinki. Because this is a retrospective study, there is no approval number for each study.

Document is current

Any future updates will be listed below